472 related articles for article (PubMed ID: 30244497)
1. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Corremans R; Adão R; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):204-215. PubMed ID: 30244497
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
3. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K; Andelfinger GU; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):865-883. PubMed ID: 32772754
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
Armenian SH
Ann Nutr Metab; 2016; 68 Suppl 3():10-14. PubMed ID: 27931027
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
6. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy.
Dozic S; Howden EJ; Bell JR; Mellor KM; Delbridge LMD; Weeks KL
Cells; 2023 May; 12(9):. PubMed ID: 37174712
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Aspects of Anthracycline Cardiotoxicity.
Russo M; Della Sala A; Tocchetti CG; Porporato PE; Ghigo A
Curr Treat Options Oncol; 2021 Feb; 22(2):18. PubMed ID: 33547494
[TBL] [Abstract][Full Text] [Related]
11. Current views on anthracycline cardiotoxicity.
Mele D; Nardozza M; Spallarossa P; Frassoldati A; Tocchetti CG; Cadeddu C; Madonna R; Malagù M; Ferrari R; Mercuro G
Heart Fail Rev; 2016 Sep; 21(5):621-34. PubMed ID: 27230651
[TBL] [Abstract][Full Text] [Related]
12. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Dempke WCM; Zielinski R; Winkler C; Silberman S; Reuther S; Priebe W
Eur J Cancer; 2023 May; 185():94-104. PubMed ID: 36966697
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity in anthracycline therapy: Prevention strategies.
Cruz M; Duarte-Rodrigues J; Campelo M
Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V
Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment.
Saleh Y; Abdelkarim O; Herzallah K; Abela GS
Heart Fail Rev; 2021 Sep; 26(5):1159-1173. PubMed ID: 32410142
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
Bhagat A; Kleinerman ES
Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens.
Cadeddu Dessalvi C; Pepe A; Penna C; Gimelli A; Madonna R; Mele D; Monte I; Novo G; Nugara C; Zito C; Moslehi JJ; de Boer RA; Lyon AR; Tocchetti CG; Mercuro G
Heart Fail Rev; 2019 Nov; 24(6):915-925. PubMed ID: 31256318
[TBL] [Abstract][Full Text] [Related]
19. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S84-92. PubMed ID: 27183529
[TBL] [Abstract][Full Text] [Related]
20. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]